Nurexone Biologic Inc
F:J90

Watchlist Manager
Nurexone Biologic Inc Logo
Nurexone Biologic Inc
F:J90
Watchlist
Price: 0.38 EUR Market Closed
Market Cap: €25.5m

Nurexone Biologic Inc
Non-Reccuring Items

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Nurexone Biologic Inc
Non-Reccuring Items Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Non-Reccuring Items CAGR 3Y CAGR 5Y CAGR 10Y
Nurexone Biologic Inc
F:J90
Non-Reccuring Items
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Enerflex Ltd
TSX:EFX
Non-Reccuring Items
-CA$42m
CAGR 3-Years
-6%
CAGR 5-Years
-74%
CAGR 10-Years
-1%
T
TerraVest Industries Inc
TSX:TVK
Non-Reccuring Items
CA$9.2m
CAGR 3-Years
N/A
CAGR 5-Years
46%
CAGR 10-Years
N/A
CES Energy Solutions Corp
TSX:CEU
Non-Reccuring Items
-CA$80k
CAGR 3-Years
N/A
CAGR 5-Years
80%
CAGR 10-Years
N/A
Secure Energy Services Inc
TSX:SES
Non-Reccuring Items
-CA$64m
CAGR 3-Years
-20%
CAGR 5-Years
-5%
CAGR 10-Years
8%
H
HydroGraph Clean Power Inc
CNSX:HG
Non-Reccuring Items
-$102.9k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Nurexone Biologic Inc
Glance View

Market Cap
25.5m EUR
Industry
N/A

NurExone Biologic, Inc. is a pharmaceutical company, which engages in the development and commercialization of biological extracellular vesicles (EV)-based technology drug platform. The company is headquartered in Edmonton, Alberta. The company went IPO on 2012-05-08. The firm is developing a biological extracellular vesicles (EV)-based technology drug platform. The technology drug platform offers treatment for reversing paralysis and improving the life of patients following spinal cord injury using bio-guided exosomes (membrane-bound extracellular vesicles) loaded with modified small interfering RNA (siRNA) sequence. Its technology is used to treat various conditions, such as spinal cord injury, traumatic brain injury, and other brain and neurological indications. The firm also has developed exosome manufacturing process. The company is also focused on exosome research, management of clinical studies and commercialization of the technology for different indications, not limited to the central nervous system.

J90 Intrinsic Value
HIDDEN
Show

See Also

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett